Gemcitabine-O-Si(di-iso)-O-Mc

• CAT Number: I045986
• Molecular Formula: C24H36F2N4O7Si
• Molecular Weight: 558.65
• Purity: ≥95%
• Synonyms: 1-[5-[[(2R,3R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4,4-difluoro-3-hydroxyoxolan-2-yl]methoxy-di(propan-2-yl)silyl]oxypentyl]pyrrole-2,5-dione
• InChI: InChI=1S/C24H36F2N4O7Si/c1-15(2)38(16(3)4,35-13-7-5-6-11-29-19(31)8-9-20(29)32)36-14-17-21(33)24(25,26)22(37-17)30-12-10-18(27)28-23(30)34/h8-10,12,15-17,21-22,33H,5-7,11,13-14H2,1-4H3,(H2,27,28,34)/t17-,21-,22-/m1/s1
• InChIKey: UANWPSOXUYWBLM-ZPMCFJSWSA-N
• SMILES: CC(C)[Si](C(C)C)(OCCCCCN1C(=O)C=CC1=O)OCC2C(C(C(O2)N3C=CC(=NC3=O)N)(F)F)O

Gemcitabine-O-Si(di-iso)-O-Mc(CAT: I045986) is a silicon-based prodrug derivative of Gemcitabine, a nucleoside analog widely used in oncology. By incorporating a di-isopropyl silyl ether with a methoxycarbonyl substituent, this modified form improves lipophilicity and stability, potentially enhancing membrane permeability and pharmacokinetic properties. Upon enzymatic or chemical activation, the prodrug releases Gemcitabine, restoring its antimetabolite activity that inhibits DNA synthesis and induces apoptosis in rapidly dividing tumor cells. This derivative is a valuable tool for studying prodrug strategies, cancer pharmacology, and nucleoside analog delivery systems, and it may provide insights into improving the therapeutic performance of Gemcitabine in solid tumors.